Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

However, our opinions are our own. See how we rate credit cards to write unbiased product reviews. Cash back credit cards do exactly what their name suggests: They earn cash back on qualifying ...